Evangelia Katsoulakis1, Jill E Duffy2, Bradley Hintze2,3, Neil L Spector2,3,4, Michael J Kelley2,3,4. 1. Department of Radiation Oncology, James A. Haley Veterans Affairs Healthcare System, Tampa, FL. 2. VA National Oncology Program Office, Durham, NC. 3. Medical Service, Durham VA Healthcare System, Durham, NC. 4. Department of Medicine and Duke Cancer Institute, Duke University Medical Center, Durham, NC.
Abstract
PURPOSE: Next-generation sequencing (NGS) multigene panel testing has become widespread, including the Veterans Affairs (VA), through the VA National Precision Oncology Program (NPOP). The interpretation of genomic alterations remains a bottleneck for realizing precision medicine. We sought to examine the concordance for pathogenicity determination and clinical actionability of annotation services in NPOP. METHODS: Unique gene variants were generated from NGS gene panel results using two sequencing services. For each unique gene variant, annotations were provided through N-of-One (NoO), IBM Watson for Genomics (WfG), and OncoKB. Annotations for pathogenicity (all three sources) and actionability (WfG and OncoKB) were examined for concordance. Cohen's kappa statistic was calculated to measure agreement between annotation services. RESULTS: Among 1,227 NGS results obtained between 2015 and 2017, 1,388 unique variants were identified in 117 genes. The genes with the largest number of variants included TP53 (270), STK11 (92), and CDKN2A (81). The most common cancer type was lung adenocarcinoma (440), followed by colon adenocarcinoma (113). For pathogenic and likely pathogenic variants, there was 30% agreement between WfG and NoO (kappa, -0.26), 76% agreement between WfG and OncoKB (kappa, 0.22), and 42% agreement between NoO and OncoKB (kappa, -0.07). For level 1 drug actionability of gene variant-diagnosis combinations, there was moderate agreement between WfG and OncoKB (96.9%; kappa, 0.44), with 27 combinations identified as level 1 by both services, 58 by WfG alone, and 6 variants by OncoKB alone. CONCLUSION: There is substantial variability in pathogenicity assessment of NGS variants in solid tumors by annotation services. In addition, there was only moderate agreement in level 1 therapeutic actionability recommendations between WfG and OncoKB. Improvement in the precision of NGS multigene panel annotation is needed.
PURPOSE: Next-generation sequencing (NGS) multigene panel testing has become widespread, including the Veterans Affairs (VA), through the VA National Precision Oncology Program (NPOP). The interpretation of genomic alterations remains a bottleneck for realizing precision medicine. We sought to examine the concordance for pathogenicity determination and clinical actionability of annotation services in NPOP. METHODS: Unique gene variants were generated from NGS gene panel results using two sequencing services. For each unique gene variant, annotations were provided through N-of-One (NoO), IBM Watson for Genomics (WfG), and OncoKB. Annotations for pathogenicity (all three sources) and actionability (WfG and OncoKB) were examined for concordance. Cohen's kappa statistic was calculated to measure agreement between annotation services. RESULTS: Among 1,227 NGS results obtained between 2015 and 2017, 1,388 unique variants were identified in 117 genes. The genes with the largest number of variants included TP53 (270), STK11 (92), and CDKN2A (81). The most common cancer type was lung adenocarcinoma (440), followed by colon adenocarcinoma (113). For pathogenic and likely pathogenic variants, there was 30% agreement between WfG and NoO (kappa, -0.26), 76% agreement between WfG and OncoKB (kappa, 0.22), and 42% agreement between NoO and OncoKB (kappa, -0.07). For level 1 drug actionability of gene variant-diagnosis combinations, there was moderate agreement between WfG and OncoKB (96.9%; kappa, 0.44), with 27 combinations identified as level 1 by both services, 58 by WfG alone, and 6 variants by OncoKB alone. CONCLUSION: There is substantial variability in pathogenicity assessment of NGS variants in solid tumors by annotation services. In addition, there was only moderate agreement in level 1 therapeutic actionability recommendations between WfG and OncoKB. Improvement in the precision of NGS multigene panel annotation is needed.
Authors: Lawrence J Jennings; Maria E Arcila; Christopher Corless; Suzanne Kamel-Reid; Ira M Lubin; John Pfeifer; Robyn L Temple-Smolkin; Karl V Voelkerding; Marina N Nikiforova Journal: J Mol Diagn Date: 2017-03-21 Impact factor: 5.568
Authors: Mark E Robson; Angela R Bradbury; Banu Arun; Susan M Domchek; James M Ford; Heather L Hampel; Stephen M Lipkin; Sapna Syngal; Dana S Wollins; Noralane M Lindor Journal: J Clin Oncol Date: 2015-08-31 Impact factor: 44.544
Authors: Luc G T Morris; Nadeem Riaz; Alexis Desrichard; Yasin Şenbabaoğlu; A Ari Hakimi; Vladimir Makarov; Jorge S Reis-Filho; Timothy A Chan Journal: Oncotarget Date: 2016-03-01
Authors: Alex H Wagner; Brian Walsh; Georgia Mayfield; David Tamborero; Dmitriy Sonkin; Kilannin Krysiak; Jordi Deu-Pons; Ryan P Duren; Jianjiong Gao; Julie McMurry; Sara Patterson; Catherine Del Vecchio Fitz; Beth A Pitel; Ozman U Sezerman; Kyle Ellrott; Jeremy L Warner; Damian T Rieke; Tero Aittokallio; Ethan Cerami; Deborah I Ritter; Lynn M Schriml; Robert R Freimuth; Melissa Haendel; Gordana Raca; Subha Madhavan; Michael Baudis; Jacques S Beckmann; Rodrigo Dienstmann; Debyani Chakravarty; Xuan Shirley Li; Susan Mockus; Olivier Elemento; Nikolaus Schultz; Nuria Lopez-Bigas; Mark Lawler; Jeremy Goecks; Malachi Griffith; Obi L Griffith; Adam A Margolin Journal: Nat Genet Date: 2020-04-03 Impact factor: 38.330
Authors: Catherine G Fischer; Aparna Pallavajjala; LiQun Jiang; Valsamo Anagnostou; Jessica Tao; Emily Adams; James R Eshleman; Christopher D Gocke; Ming-Tseh Lin; Elizabeth A Platz; Rena R Xian Journal: Clin Cancer Res Date: 2022-06-01 Impact factor: 13.801
Authors: David Bick; Sarah L Bick; David P Dimmock; Tom A Fowler; Mark J Caulfield; Richard H Scott Journal: Am J Med Genet C Semin Med Genet Date: 2020-12-22 Impact factor: 3.908
Authors: Kenneth D Doig; Christopher G Love; Thomas Conway; Andrei Seleznev; David Ma; Andrew Fellowes; Piers Blombery; Stephen B Fox Journal: BMC Med Genomics Date: 2022-03-26 Impact factor: 3.063
Authors: Samantha O Perakis; Sabrina Weber; Qing Zhou; Ricarda Graf; Sabine Hojas; Jakob M Riedl; Armin Gerger; Nadia Dandachi; Marija Balic; Gerald Hoefler; Ed Schuuring; Harry J M Groen; Jochen B Geigl; Ellen Heitzer; Michael R Speicher Journal: ESMO Open Date: 2020-09